| Clinical
Studies |
| |
Endpoints for disease progression, amelioration or stability, adjusted for
new therapeutic modalities.
Chairpersons: R. Neumann & B. S. Christiansen
|
| Glaucoma
R. Feldman |
| Inflammation
R. Vogel |
| Retinal,
macular disease
B. Kuppermann |
| Diabetic
retinopathy
J. Cunha-Vaz |
| Closing
remarks
W. Chambers |
| Ethical
dilemmas |
| |
The autonomy of patient physician relationship in clinical studies.
T. Arnold |
|
| Patent rights and society's interests
M. Moser |
|
Academia
- Industry - Regulatory bodies relationship:
Moderator:
R. Vogel |
|
| The influence of the pharmaceutical
industry and regulatory bodies on research topics and methodologies in academic
institutions.
Panel: N. Agarwal, M. Belkin, J. Cheetham, S.B. Christiansen,
J. Cunha-Vaz, K. H. Geldsetzer, B. Matthews, W. Chambers |
| Technology
and cost |
| |
Unrealistic expectations of inventors as opposed to the real price/time in the
industrial world.
M. Delmage |
|
| The postgenomic landscape- opportunties
for groundbreaking drugs and personalized medicine
Y. Koltin |
Evidence
based medicine: Conventional
and complementary alternative medicine
Moderator:
L. Levin |
| Complementary
alternative medicine in the 3rd millennium: The difficulty of applying conventional
standards to non standard medicine
S. Pintov |
|
Panel: R. Wormald, S. Lightman, S. Pintov, P. Asbell, E.
Strahlman, W. Chambers
- Benefits
- Managing
patients that do not meet "inclusion criteria" of "well controlled"
studies
- Are all studies created equal? Hidden biases - can we tell?
- Meta
- analyses
- Regulated medicine
|
